Zoom on Angiostamp™800, a tumor targeting contrast agent for fluorescence and photoacoustic imaging.
AngiostampTM800 was initially developed as a NIR contrast agent for tumor detection using fluorescence imaging. OPTIMAL Grenoble has recently shown that it can be used for detecting tumors with high resolution at depth using photoacoustic imaging.
Angiostamp™800 is an organic contrast agent targeting tumors via the specific recognition of αvβ3 integrin, a cell surface receptor involved in cell adhesion and migration. This integrin is overexpressed on endothelial cells during neoangiogenesis as well as on many tumor cells types.
Angiostamp™800 has been widely characterized and was shown to provide high tumor contrast in many in vivo tumor models including glioblastoma, osteosarcoma, head and neck, breast, prostate, liver, lung and ovarian cancers, as well as in a multiple metastases models.
Angiostamp™800 is now available for the scientific community who aims at following cancer development non-invasively using fluorescence or photoacoustic imaging and can be provided by OPTIMAL Grenoble www.imagerie-optimal.fr.
